In immunocompetent murine models of lymphoma and neuroblastoma, IT rotavirus therapy demonstrated that it can overcome immune checkpoint inhibitor resistance.
In a post-hoc analysis of the ASPIRE trial results, in which carfilzomib was discontinued due to a lack of long-term safety data, researchers present the safety and efficacy findings of KRd vs Rd for relapsed multiple myeloma at 18 months from randomization.
Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.
Nonrandomized trial demonstrates tolerability and antitumor activity of a PD-1 checkpoint inhibitor plus a VEGF-TKI in patients with treatment-naïve advanced RCC.
In this retrospective study, researchers sought to determine if cancer patients with rheumatologic disease would be able to tolerate cancer treatment with immune checkpoint inhibitors or if these agents would induce a rheumatologic disease flare.
Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.
Results of the double-blind phase 3 CELESTIAL study, presented at the 2018 Gastrointestinal Cancers Symposium, demonstrated efficacy of cabozantinib in patients with HCC who were previously treated with sorafenib.
Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).
FDA grants Breakthrough Therapy designation for ribociclib as an initial endocrine-based therapy for HR+/HER2- breast cancer in premenopausal or perimenopausal women.
Results of a double-blind phase 2 study determined if adding oral pazopanib to intravenous paclitaxel improved outcomes for women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
The efficacy and safety of venetoclax in patients with relapsed/refractory CLL that progressed during or after ibrutinib therapy was determined in an open-label, phase 2 study.
Using a mouse model of HER2+ breast cancer, researchers tested the efficiency of combined epigenetic modulation and checkpoint inhibition using the histone deacetylase inhibitor ENT and antibodies for 2 checkpoint inhibitor proteins. These findings were presented at the 2017 SABCS.
Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.
Breast cancer was previously thought to not be immunogenic in nature, but a subset of patients with breast cancer, primarily with triple negative disease, have exhibited robust levels of tumor infiltrating leukocytes.
US FDA approval of dasatinib is extended to pediatric patients with Ph+ CML based on data from 2 open-label, nonrandomized trials involving 97 patients.
A review of granulocyte colony-stimulating factors, dosage and administration, adverse effects, and nurse management steps is presented.
A phase 2 study compared ruxolitinib with best-available therapy as second-line treatment for patients with high-risk essential thrombocythemia or polycythemia vera who became intolerant of first-line therapy.
Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.
Results of a retrospective single-center study showed that response to rituximab vs splenectomy as second-line therapy for steroid-refractory ITP was not significantly different between the 2 treatments.
Lenalidomide reduced the relative risk of disease progression in a clinical trial of patients with chronic lymphocytic leukemia who did not achieve MRD negative disease state after first-line chemoimmunotherapy.
Investigators report that administering cannabis to patients with cancer undergoing immunotherapy was found to lower the response rate to therapy but had no effect on PFS or OS, in an oral presentation at ESMO 2017 Congress.
Patients with multiple myeloma treated with daratumumab who experience IRRs may easily be managed by administering pre-infusion and postinfusion medications, investigators reported in a presentation at ESMO 2017 Congress.
The first FDA approval of a CAR T cell therapy is granted for the treatment of B-cell precursor ALL. FDA also approves rheumatoid arthritis medication for the management of cytokine release syndrome, a common and serious adverse effect of CAR T cell therapy
Do monoclonal antibodies other than daratumumab cause false positives in the blood antibody screen and crossmatch obtained prior to a transfusion?
Inotuzumab ozogamicin (Besponsa), an antibody-drug conjugate comprised of a monoclonal antibody that targets CD22 linked to the cytotoxic agent calicheamicin, was granted FDA approval for the treatment of R/R B-cell precursor ALL.
In this review, investigators discuss current and emerging treatments for acute lymphocytic leukemia and acute myeloid leukemia in pediatric patients.
Immunotherapy regimens FDA-approved for the treatment of melanoma may also be an option for a rare and aggressive form of papillary thyroid cancer.
A multidisciplinary education initiative was instrumental in preparing nursing and clinical staff for the challenges of managing care and follow-up of patients undergoing CAR-T therapy.
The medications so far show little efficacy in children with cancer, but new studies may provide clues to how to change this, pediatric oncologist says.
Study also provides evidence supporting an anti-tumor effect associated with a single preoperative dose of pembrolizumab.
Sign Up for Free e-newsletters
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
- FDA Approves Fostamatinib for ITP After Insufficient Response to Previous Treatment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|